Trial result ·
Effect of APOC3 Inhibition With Olezarsen on Coronary Atherosclerosis: Essence-TIMI 73b Imaging Study.
Written based on 1 research study on PubMed, searched on 5 Nov 2026.
What was studied
This trial tested a drug called olezarsen in adults with high blood fats called triglycerides. The rise was largely moderate. 468 people took part. 349 got olezarsen and 119 got a dummy shot. Each had a CT scan of heart arteries that showed plaque that was not calcified. Scans were repeated at 12 months. The aim was to see if plaque volume changed.
What they found
At 6 months, olezarsen lowered triglycerides, remnant cholesterol and apoB more than placebo. LDL cholesterol did not differ between the groups. At 12 months, the change in plaque volume did not differ between olezarsen and placebo. Plaque that was calcified, plaque with low attenuation and total plaque did not differ either. People also took standard drugs to lower blood fats.
What it means for patients
The authors say olezarsen did not affect coronary plaque volume at 12 months. This held even though it clearly lowered triglycerides and remnant cholesterol.
Why it is not certain yet
The scans covered 12 months. The abstract does not say if longer use would change plaque. Results apply to adults with a moderate rise in triglycerides who already took standard drugs. The abstract does not give results on heart attacks or other events.
The registered trial
The paper names this trial from a public trial registry. Its page shows who the trial is for, its sites and its status.
Source
Effect of APOC3 Inhibition With Olezarsen on Coronary Atherosclerosis: Essence-TIMI 73b Imaging Study.
PubMed · PMID 41910513We restate facts from the source record in our own words. The original wording belongs to its publisher.
This page is not medical advice. Talk to your doctor about your own care.
Back to Coronary artery disease publications